Lonvi Biosciences (sometimes stylized as LONVI), a longevity-focused startup based in Shenzhen, China, is actively developing anti-aging supplements in the form of pills or capsules centered on procyanidin C1 (PCC1), a natural polyphenolic compound derived from grape seed extract. Founded around 2022, the company specializes in “biomarker-driven senotherapeutics,” targeting senescent cells—dysfunctional, aged cells that accumulate over time and contribute to aging-related diseases by promoting inflammation and tissue decline.
Key Details on Their PCC1-Based Development
• Mechanism of Action: PCC1 acts as a senolytic (selectively eliminating senescent cells) and senomorphic (suppressing their harmful secretions without killing them). Preclinical studies, including research from Shanghai scientists, showed it extended mouse lifespan by 9.4% overall and by 64.2% from the treatment start point, while improving health markers like skin and tissue renewal. It protects healthy cells during this process, unlike broader chemotherapy agents.
• Products: Lonvi has launched early-stage products like the “PCC1 Senolytic Complex | 199 Clinic Edition,” a plant-based supplement available on their site. It’s positioned as a daily pill for supporting cellular health, with an ongoing early human pilot study (n=17, ages 50–86) reporting improvements in senescence biomarkers after just 3 days. They emphasize it’s for exploration, not medical advice, and share raw preclinical data (methods PDF and Excel results) openly on their website.
• Leadership Vision: Chief Technology Officer Lyu Qinghua (also referred to as Liu Qinghua in some reports) has publicly stated that living to 150 years is “definitely realistic” and could become a reality soon, reflecting China’s growing investment in anti-aging tech amid its demographic challenges.
This work builds on broader Chinese efforts in longevity science, including “immortality islands” and other labs, but Lonvi’s approach is notably grounded in natural compounds for accessibility. While promising in animal and small human pilots, human clinical trials for longevity endpoints are still nascent.
~Grok